The FDA approved the poly ADP ribose polymerase (PARP) inhibitor in June 2023 in combination with enzalutamide for men with ...

Pfizer Inc. (NYSE:PFE) has unveiled major advances in cancer research at the 2025 ASCO Annual Meeting, spotlighting robust ...

Cancer remains one of the biggest health challenges of our lifetime. Millions of people globally receive a cancer diagnosis each year — in the United States, that’s about one diagnosis every 30 ...

The drug is already approved to treat non-metastatic castration-resistant prostate cancer (CRPC), but expansion ... Johnson's Erleada (apalutamide) and Pfizer/Astellas' Xtandi (enzalutamide ...

NICE has rejected Johnson & Johnson’s oral prostate cancer drug Erleada (apalutamide ... COVID-19 pandemic include the option of giving Pfizer/Astellas androgen receptor inhibitor Xtandi ...

What are the best stocks right now for investors in the cancer drug development space? Seeking Alpha analysts offer their ...

ASCO 2025 will showcase cutting-edge advancements in precision medicine, artificial intelligence, and biomarker-driven ...

Halozyme Therapeutics, Inc. ("Halozyme") today announced that Dr. Helen Torley, president and chief executive officer, is scheduled to participate and host investor meetings at the following investor ...

BioNTech SE(Nasdaq: BNTX, "BioNTech" or "the Company") will present clinical trial data from select pipeline candidates across the Company's diversified oncology portfolio ...

During a live event, Chandler H. Park, MD, and event participants looked at quality of life, tolerability, and rechallenging ...

Pharmaceutical companies are making billions on treatments that can sometimes overpromise and underdeliver for terminal cases ...